Vascular extracellular matrix hydrogel
Provided herein are methods of making an ECM gel from vascular tissue. Also provided herein are ECM compositions prepared from vascular tissue, and methods of use of those compositions, for example in treatment of aneurysms, and for vascularization or re-vascularization.
1. An extracellular matrix (ECM) composition consisting essentially of devitalized, acid-protease-digested ECM derived from vascular adventitial tissue delaminated from the medial layer, having a pH of from 6.8 to 7.8, wherein the ECM composition does not include ECM derived from the medial layer.
2. The composition of claim 1 , wherein the devitalized, acid-protease-digested ECM is not dialyzed or chemically crosslinked.
3. The composition of claim 1 , wherein the vascular adventitial tissue is bovine, ovine, or porcine vascular adventitial tissue.
4. The composition of claim 1 , wherein the vascular adventitial tissue is aortic adventitia.
5. The composition of claim 1 , further consisting essentially of an acid protease.
6. The composition of claim 5 , wherein the acid protease is trypsin or pepsin.
7. The composition of claim 1 , wherein the composition forms a gel when warmed to 37° C.
8. The composition of claim 1 , wherein the vascular adventitial tissue is arterial adventitia.
9. The composition of claim 1 , wherein the pH is from 7.2 to 7.6.
10. An extracellular matrix (ECM) hydrogel consisting essentially of devitalized, acid-protease-digested extracellular matrix derived from vascular adventitial tissue delaminated from the medial layer and an acid protease, the hydrogel having a pH of from 6.8 to 7.8, wherein the hydrogel does not include ECM derived from the medial layer.
11. The ECM hydrogel of claim 10 , wherein the acid protease is pepsin or trypsin.
12. The ECM hydrogel of claim 10 , wherein the vascular adventitial tissue is aortic or arterial adventitial tissue.
13. The ECM hydrogel of claim 10 , wherein the pH is in the range of 7.2 to 7.6.
14. The ECM hydrogel of claim 10 , wherein the pH is 7.4.
15. The ECM hydrogel of claim 10 , wherein the hydrogel exhibits reverse thermal gelation and has a sol to gel transition in the range of 20° C. to 35° C.
16. The ECM hydrogel of claim 10 , wherein the hydrogel comprises longer fibers and at least 50% lower Fibroblast Growth Factor-1 (FGF-1) or Fibroblast Growth Factor-2 (FGF-2) content compared to an ECM hydrogel made from ECM derived from small intestinal submucosa.
17. The ECM hydrogel of claim 10 , wherein the hydrogel comprises increased Heparin Binding EGF Like Growth Factor (HB-EGF) content and/or lower content of one or more of Angiopoietin 2, Endostatin, Insulin Like Growth Factor Binding Protein 1 (IGFBP1), Pentraxin 3 (PTX3), Prolactin, Serpin B5, or TIMP Metallopeptidase Inhibitor 4 (TIMP4) as compared to an ECM hydrogel made from devitalized, acid-protease-digested extracellular matrix derived from porcine small intestine submucosa.
18. The ECM hydrogel of claim 10 , wherein the hydrogel is in gel form at 37° C.
19. A composition of an acidic solution consisting essentially of devitalized, acid-protease-digested extracellular matrix (ECM) derived from vascular adventitial tissue delaminated from the medial layer, and an acid protease, wherein the composition does not include ECM derived from the medial layer.
20. The composition of claim 19 , wherein the protease is trypsin or pepsin.
21. The composition of claim 19 , wherein the pH of the acidic solution is from 1 to 4.
22. The composition of claim 19 , wherein the pH of the acidic solution is 2.0±0.3.
23. The composition of claim 19 , wherein when the acidic solution is neutralized, the solution forms a gel when warmed to 37° C.
24. The composition of claim 19 , wherein the acid protease is pepsin or trypsin.
25. The composition of claim 19 , wherein the vascular adventitial tissue is aortic or arterial adventitial tissue.